Introduction
Deorphanization of GPCRs remains an active area of research, especially considering that approximately 40% of all approved drugs for humans target only a small fraction of the GPCRome (1, 2) . In addition to elucidating the pharmacology of orphan GPCRs, it is crucial to characterize the anatomical locations and physiological functions of these receptors in vivo. G protein-coupled receptor 182 (GPR182, formerly known as G10D or adrenomedullin receptor [ADMR] ) (3, 4) , is a class A orphan GPCR with very little known about its expression, function, regulation, or pharmacology. GPR182 is grouped within the chemokine receptor family by phylogeny, with the atypical chemokine receptor 3 (ACKR3, formerly known as CXCR7 or RDC1) as its closest paralog, despite the two sharing a modest, less-than-30% sequence homology in mice and humans. GPR182 was previously considered a putative receptor for the multifunctional peptide adrenomedullin (4) , however, these initial findings were not consistent among laboratories (5) , and it was later shown that adrenomedullin signals through a different GPCR complex (6) . Unfortunately, the former ADMR nomenclature is sometimes still used, which leads to confusion in the field. For example, GPR182 was reported to be expressed in numerous human pancreatic cancer cell lines, and knockdown of GPR182 in these cells decreased xenograft tumor growth, which the authors concluded was due to a loss of adrenomedullin signaling (7, 8) . Anatomical expression profiling of the GPCRome demonstrated the relatively ubiquitous low expression of Gpr182 in most mouse tissues (9) . More recently, Gpr182 was found to be highly expressed in developing murine and zebrafish endothelium and enriched in mammary tumor endothelium compared with normal mammary endothelium (10) (11) (12) . Additionally, Gpr182 was identified among a group of factors that are significantly altered in a zebrafish model of myeloid leukemia (13) . Thus, a significant advance of the current study is to map the expressional profile of Gpr182 using an in vivo mammalian reporter model, in which, in addition to the endothelium of numerous tissues, we observed expression within the gastrointestinal tract epithelia.
The epithelium of the gastrointestinal tract is one of the most dynamic tissues in the adult body and is primarily responsible for the absorption of dietary nutrients and also for fulfilling important endocrine, immune, and protective barrier functions. To maintain its proper functions, the intestinal epithelium must undergo continuous turnover, with the entire small intestinal epithelium renewing every week in humans and in mice. This constant renewal is driven by an active population of intestinal stem cells (ISCs) that are located at the base of the crypts of Lieberkühn, where they give rise to rapidly dividing daughter transit-amplifying progenitor cells that differentiate into the absorptive or secretory lineages responsible for functions of the intestine (14) (15) (16) (17) . Current views hold that Orphan GPCRs provide an opportunity to identify potential pharmacological targets, yet their expression patterns and physiological functions remain challenging to elucidate. Here, we have used a genetically engineered knockin reporter mouse to map the expression pattern of the Gpr182 during development and adulthood. We observed that Gpr182 is expressed at the crypt base throughout the small intestine, where it is enriched in crypt base columnar stem cells, one of the most active stem cell populations in the body. Gpr182 knockdown had no effect on homeostatic intestinal proliferation in vivo, but led to marked increases in proliferation during intestinal regeneration following irradiation-induced injury. In the Apc Min mouse model, which forms spontaneous intestinal adenomas, reductions in Gpr182 led to more adenomas and decreased survival. Loss of Gpr182 enhanced organoid growth efficiency ex vivo in an EGF-dependent manner. Gpr182 reduction led to increased activation of ERK1/2 in basal and challenge models, demonstrating a potential role for this orphan GPCR in regulating the proliferative capacity of the intestine. Importantly, GPR182 expression was profoundly reduced in numerous human carcinomas, including colon adenocarcinoma. Together, these results implicate Gpr182 as a negative regulator of intestinal MAPK signaling-induced proliferation, particularly during regeneration and adenoma formation.
Y)-box 9 (Sox9), our understanding of both of these ISC populations has drastically expanded over the past decade (19) (20) (21) (22) (23) (24) (25) (26) . It is evident that the activity and proliferation of these ISCs must be tightly controlled by numerous signaling pathways and redundant mechanisms in order to maintain homeostasis in the dynamic gut microenvironment (14, 27) . Furthermore, oncogenic mutations specifically in ISCs can drastically enhance adenoma formation in mice (20, 28) . Thus, defining the factors that regulate ISC proliferation and survival is critical in order to better understand ISC function during homeostasis, damage repair, and cancer and, hence, to better therapeutically target these ISCs.
2 distinct pools of ISCs exist in the intestinal epithelium: the crypt base columnar (CBC) ISCs, which are positioned between differentiated Paneth cells and mediate normal homeostatic renewal, and "damage-resistant" ISCs, which act as reserve ISCs that are activated following injury (14, 15, 17, 18) . With the discovery of numerous ISC-specific markers including leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5), leucine-rich repeats and Ig-like domains 1 (Lrig1), achaete-scute family bHLH transcription factor 2 (Ascl2), olfactomedin 4 (Olfm4), HOP homeobox (Hopx), telomerase reverse transcriptase (Tert), BMI1 proto-oncogene, polycomb ring finger (Bmi1), and SRY (sex-determining region (29, 62, 63) . The GPR182 protein-coding region is shaded in pink. mGPR182, murine GPR182. (B) Whole-mount X-gal staining of E8 Gpr182 lacZ/lacZ embryo. DA, dorsal aorta; VV, vitelline vein. (C) Optical projection tomography of whole-mount X-gal-stained WT and Gpr182 lacZ/lacZ E13.5 embryos. X-Gal staining in Gpr182 lacZ/lacZ E13.5 heart (D) and E17.5 lung, kidney, liver, yolk sac, and stomach, pancreas, and duodenum (E). Representative Gpr182 lacZ expression in adult heart (F), lung (G), kidney (H), liver (I), glandular stomach (J), and colon (K) stained with X-gal and/or β-gal (green). Sections were costained with DAPI (purple) and either the endothelial marker CD31 (F) or the podocyte marker podoplanin (PDPN) (H). X-Gal-stained sections were counterstained with eosin (F-H) or Neutral Red (D and I-K). Scale bars: 200 μm (B and D), 1 mm (C, E, and K), and 100 μm (F-J). jci.org Volume 127 Number 2 February 2017
with levels in Gpr182 +/+ Cre controls (Supplemental Figure 1A) . Like the Gpr182 lacZ/lacZ mice, the Gpr182 Δ/Δ CMV-Cre-KO mice were born at expected Mendelian ratios and lived to adulthood with no observed phenotypic abnormalities.
We detected expression of Gpr182 lacZ by β-gal activity as early as E8.0 in dorsal aorta and vitelline veins ( Figure 1B and Supplemental Figure 2A ), similar to previously published ISH observations (10) . By E13.5, we observed Gpr182 expression in numerous organs including heart, lung, liver, aorta, and carotid arteries (Figure 1C and Supplemental Figure 2 , B and C). Expression of Gpr182 in embryonic heart was detected in both atria and ventricles, particularly in the ventricular trabecular region ( Figure 1D ). At E17.5, Gpr182 localization remained prominent in the heart, lungs, and liver, but was also observed in embryonic kidneys, glandular stomach, intestine, spleen, and yolk sac vasculature ( Figure 1E and Supplemental Figure 2D ).
In adult mice Gpr182 was widely expressed throughout the body. Cardiac expression was localized to the endocardium of the atria and ventricles, as well as in the heart valves and coronary arteries ( Figure 1F and Supplemental Figure 2E ). Notably, we observed little to no staining in cardiomyocytes, fibroblasts, epicardium, or capillary endothelium. Lungs expressed high levels of Gpr182 primarily in endothelial cells ( Figure 1G , Supplemental Figure 1C and Supplemental Figure 2F ). Though Gpr182 was expressed in renal In this study, we aimed to identify novel functions of the orphan GPR182 in vivo by first mapping the murine Gpr182 expression pattern during development and in adulthood, and then next elucidating the effects of Gpr182 reduction on intestinal homeostasis, regeneration, and adenoma formation.
Results
Orphan GPR182 is widely expressed throughout development and adulthood. The Gpr182 tm2a(KOMP)Wtsi/+ mouse (hereafter referred to as the Gpr182 lacZ/+ mouse) was generated and used to both map the murine Gpr182 expression pattern during development and adulthood as well as act as a loss-of-function model (29) . A gene trap cassette bearing an En2 splice acceptor upstream of a lacZ reporter was knocked into the murine Gpr182 locus immediately downstream of exon 1, resulting in expression of lacZ instead of the endogenous protein-coding sequence in exon 2 ( Figure 1A ). When crossed to achieve homozygosity, the Gpr182 lacZ/lacZ animals had a significant reduction of approximately 85% in endogenous Gpr182 expression in jejunum and negligible levels in other tissues compared with Gpr182 +/+ mice (Supplemental Figure 1 , A and B; supplemental material available online with this article; doi:10.1172/JCI87588DS1). When crossed with the ubiquitously expressed CMV-Cre mouse, the resulting Gpr182 Δ/Δ CMV-Cre mice had undetectable Gpr182 expression in the jejunum compared Gpr182 X-gal staining was also robust in spermatocytes of the adult testis (Supplemental Figure 2I ). Spleen and lymph nodes revealed endothelial Gpr182 localization, with little to no detectable staining in mature or developing hematopoietic and lymphoid lineages (Supplemental Figure 2 , J and K). We observed little to no X-gal staining in skeletal muscle, pancreas, brain, spinal cord, or dorsal root ganglia of adult mice (Supplemental Figure 2 , L-O).
Gpr182 is expressed throughout the intestine and is enriched in small ISCs. Whole-mount X-gal staining and histology revealed an interesting pattern of staining in the crypt epithelial cells of the small intestine, with only a few positively stained secretory cells in the villi and relatively little staining in enterocytes or submucosal endothelial cells (Figure 2 , A and B, and Supplemental Figure  3) . We found that β-gal staining was most intense in the stem cell tubules during late gestation (Supplemental Figure 2D) , we found that adult renal localization was primarily enriched in the glomeruli, where it appeared strikingly specific to podocytes ( Figure 1H and Supplemental Figure 2G ). Sinusoidal endothelial cells, rather than hepatocytes, were the primary cell type expressing Gpr182 in the liver ( Figure 1I ). We found that Gpr182 was expressed throughout the fundus and antrum ( Figure 1J , Supplemental Figure 2H , and Supplemental Figure 3) . Interestingly, this Gpr182 localization was detected in gastric epithelial cells primarily near the base of the glands in both fundus and antrum, although we observed a few lacZ + cells higher up the gland in the fundus. We did not detect staining in acid-secreting parietal cells ( Figure 1J and Supplemental Figure 3 , B and C). We detected X-gal staining in the distal colon, also at the base of the crypts ( Figure 1K and Supplemental Figure 3) . Figure 3) . To further verify the enrichment of Gpr182 in CBC ISCs in models without altered Gpr182 expression, the Lgr5-EGFP and Sox9-EGFP BAC-Tg mice were used to isolate different intestinal epithelial cell populations with distinct levels of EGFP, as previously described (18, 19, 25, (30) (31) (32) Figure 2G ). Furthermore, Gpr182 expression was very low in isolated Paneth cells. Consistent with the previous observation of rare β-gal + cells in the villus region, we found that Gpr182 also was enriched in the Sox9-EGFP High cell population, which is a mixed population of enteroendocrine cells, tuft cells, and activatable reserve ISCs (18, 31, 32) . While Gpr182 is not exclusively expressed in CBC ISCs, like Lgr5, these data provide evidence that Gpr182 is enriched in CBC ISCs at the crypt base, as well as in the Sox9-EGFP High cell population that contains activatable reserve ISCs.
Gpr182 reduction does not alter intestinal proliferation during homeostasis in vivo.
To evaluate the potential roles of GPR182 in ISCs, we first characterized intestinal proliferation during homeostasis in Gpr182 lacZ/lacZ mice and, consistent with the highly regulated nature of the ISC niche, we found no significant effects of Gpr182 reduction on homeostatic intestinal proliferation. For example, small intestine and colon lengths were unchanged in the Gpr182 lacZ/lacZ animals compared with that observed in controls ( Figure 3A and Supplemental Figure 4A ). Intestinal crypt density, as a proxy for crypt fission, was unaltered between the genotypes ( Figure 3B ). Crypt depth was also unchanged, consistent with no significant differences in basal proliferation, as evidenced by similar numbers of EdU + cells per crypt, across the genotypes in both the small intestine and colon ( Figure 3F ). Additionally, expression levels of cyclin D1 (Ccnd1) and Lgr5 were unchanged in the Gpr182 Δ/Δ CMV-Cre mouse jejunum compared with levels detected in Gpr182 +/+ CMV-Cre controls ( Figure 3G ). Expression of the Notch targets Olfm4 and Hes1 as well as the differentiation markers Chga and Lysozyme were not significantly altered in these mice. Collectively, these data demonstrate that genetic reduction of Gpr182 does not lead to altered intestinal proliferation in vivo, which is consistent with the highly regulated control of intestinal proliferation during homeostasis.
Mice with Gpr182 knockdown show intestinal hyperproliferation during intestinal regeneration following irradiation injury. To test whether GPR182 may be involved with regulating proliferation during intestinal regeneration following damage, Gpr182 +/+ and Gpr182 lacZ/lacZ mice were exposed to a high dose (14 Gy) of ionizing radiation delivered to the abdomen. It is well established that intestinal irradiation (IRR) causes apoptosis of actively dividing cells, leading to the temporary loss of proliferative crypts and villi, with subsequent surviving ISCs expanding and regenerating the damaged intestinal epithelium and peak proliferation occurring 5 days after IRR (18, (32) (33) (34) (35) . Both Gpr182 +/+ and Gpr182 lacZ/lacZ IRR animals lost approximately 20% of their initial BW 5 days after IRR compared with the non-IRR controls ( Figure 4A) . Interestingly, the small intestine and colon were significantly longer in the Gpr-182 lacZ/lacZ IRR mice compared with controls ( Figure 4B and Supplemental Figure 4A ). During regeneration, Gpr182 lacZ/lacZ IRR mouse small intestines had significantly increased crypt depth compared with that seen in IRR control mice ( Figure 4C ). While X-gal staining was observed in crypts throughout the small intestine in non-IRR Gpr182 lacZ/lacZ mice ( Figure 4D and Supplemental Figure 3A ), the vast majority of regenerative crypts in the Gpr182 lacZ/lacZ IRR mice were X-gal negative ( Figure 4D ). Gpr182 expression in whole jejunum was decreased at this phase of regeneration in Gpr182 +/+ mice compared with expression in non-IRR controls ( Figure 4E Mice with reduced Gpr182 that carry the Apc Min/+ allele have increased intestinal adenoma burden and decreased survival. Since Gpr182 acts to inhibit proliferation during regeneration, we reasoned that Gpr182 levels may also be important in deregulated proliferation during disease, such as intestinal adenoma and carcinoma. Gpr182 lacZ/lacZ adults up to 2 years of age did not develop spontaneous intestinal adenomas (n = 6; data not shown). Thus, to investigate whether Gpr182 is involved in intestinal adenoma initiation and progression, Gpr182 lacZ/lacZ mice were crossed with the well-characterized Apc Min mouse model, which develops spontaneous intestinal and colonic adenomas caused by aberrant activation of the Wnt/β-catenin signaling pathway (36, 37 ly lower BW at 5 months compared with the BW of sex-matched controls ( Figure 5B ). The spleens from both Gpr182 lacZ/+ and Gpr-182 lacZ/lacZ animals weighed significantly more when compared with spleen weights of controls ( Figure 5C ). The small intestines were also significantly longer in the Gpr182 lacZ/lacZ Apc Min/+ animals compared with control small intestine lengths ( Figure 5D ), which was similar to the response in mice treated with IRR ( Figure 4C ). Together, these data suggest that attenuated Gpr182 expression , Gapdh, and 18S. Scale bars: 5 mm (E) and 100 μm (H and I). Biological replicates: n = 25-100 mice per genotype (A); n = 10-20 mice per genotype per sex (B); n = 700-1,700 polyps from 20 to 35 mice per genotype (C, D, F, and G) ; n = 15-60 polyps from 5 mice (J); and n = 3-5 mice per genotype (K). *P < 0.05, **P < 0.01, and ***P < 0. (Figure 5K) . Consistent with the highly mosaic nature of adenomas (38, 39) , macroscopic and histologic analysis of Gpr182-associated X-gal and β-gal antibody staining revealed a mosaic staining pattern between polyps and within individual polyps (Supplemental Figure 5) . We consistently observed X-gal staining in microadenomas (Supplemental Figure 5C) , and polyp Ki67-labeled proliferation appeared inversely correlated with Gpr182 β-gal staining, supporting the notion of heterogeneous Gpr182 promoter activity (Supplemental Figure 5 , D and E). Together, these data support the idea that GPR182 plays a role in preventing adenoma formation, but it does not appear to directly alter adenoma progression.
Loss of Gpr182 increased single-cell organoid growth efficiency. Considering the proliferative phenotypes observed during regeneration and adenoma formation in Gpr182 lacZ/lacZ animals, we sought to determine whether the loss of Gpr182 altered intestinal stem cell numbers and/or proliferative capacity. We isolated single crypt epithelial cells from Gpr182 +/+ CMV-Cre and Gpr182 Δ/Δ CMVCre jejunum using FACS to select CD326 + CD44
+ cells, as previously reported (40, 41) . Neither the percentage of CD326 + epithelial cells nor the proportion of CD44 -and CD44 + epithelial cells was altered with the loss of Gpr182 (Supplemental Figure 6, A and B Figure 5H ). Furthermore, there were no qualitative or quantitative differences in overall proliferation within individual polyp cross-sec- 
Decreased GPR182 is correlated with aberrant ERK1/2 activation during homeostasis, regeneration, and in Apc
Min/+ mice. Class A GPCRs commonly activate or inhibit the MAPK signaling cascade, which has numerous downstream effects on cell proliferation and survival, but the signal transduction pathways of the orphan GPR182 have not been characterized. ERK1/2 signaling was localized in both epithelial and nonepithelial cells in the small intestine.
er organoids than did Gpr182 +/+ mice ( Figure 6 
, B-D). A number of these Gpr182
Δ/Δ organoids were X-gal + and had an increased number of p-histone H3 + cells (Supplemental Figure 6 , E and F). These data demonstrate that isolated ISCs from these animals have increased survival and proliferative potential ex vivo and further the conclusion that GPR182 acts to regulate the proliferative capacity of ISCs in the small intestine. . GAPDH was used as a loading control. Biological replicates: n = 5-10 mice per genotype per condition. *P < 0.05 and **P < 0.01, by unpaired t test. (B) Model summarizing GPR182 β-gal expression pattern (blue) in the whole mouse (heart, lungs, liver, stomach, small intestine, colon, kidney, and testis), with more specific expressional detail within the small intestine. GPR182 functions to inhibit ERK1/2 signaling to regulate the proliferative capacity of the intestine. jci.org Volume 127 Number 2 February 2017
that GPR182 expression was significantly lower in colon adenocarcinoma when compared with expression levels in patientmatched normal colon tissue ( Figure 8 ) and nonmatched samples (normal colon: 0.86 ± 0.17, n = 41; colon adenocarcinoma: 0.24 ± 0.04, n = 285; ***P < 0.0001, by Mann-Whitney t test). GPR182 expression was also significantly downregulated in numerous carcinomas in tissues other than the colon, including bladder, breast, bile duct, kidney, liver, lung, pancreas, thyroid, and uterine carcinomas ( Figure 8 ). While loss of GPR182 may not drive carcinoma initiation in mice, these data further support the idea that low GPR182 expression is inversely correlated with increased proliferative capacity in mice and humans.
Discussion
We generated and used a genetic Gpr182-lacZ-knockin mouse model to gain insights into the tissue localization and physiological functions of GPR182. Although it is possible that genetic reduction of Gpr182 expression may influence its lacZ reporter localization, our characterization using the lacZ reporter is entirely consistent with previously published ISH and microarray data (9, 10), as well as expression analysis from GPR182-independent models, including Lgr5-EGFP and Sox9-EGFP mice. The intestinal expression pattern -particularly the crypt localization -piqued our interest and became the focus of this study. However, it is worth emphasizing that Gpr182 is expressed in a variety of tissues and cell types, particularly in the endothelium, which will certainly prompt additional physiological studies. Furthermore, these types of physiological in vivo studies may prove instructive with regard to the eventual "deorphanization," or identification, of endogenous ligand(s) of GPR182, which currently remains unknown. Our study shows that Gpr182 is expressed in the epithelium throughout the gastrointestinal tract and is particularly enriched in the CBC ISCs of the small intestine. Like LGR5, GPR182 is a GPCR enriched in ISCs but appears to be a less selective ISC marker. The genetic reduction of Gpr182 did not alter intestinal morphology or proliferation during homeostasis in vivo, which is consistent with the tightly regulated control of epithelial proliferation During homeostasis, epithelial p-ERK1/2 appeared highest in the transit-amplifying zone and right above the crypt, with relatively little activity in the crypt base ISCs (Figure 7 , A and B) (43) . However, during regeneration and in Apc Min/+ animals, p-ERK1/2 was much higher throughout the epithelium, especially at the base of crypts ( Figure 7A ). Mosaic p-ERK1/2 was also observed within adenomas from Apc Min/+ animals (Supplemental Figure 5F ). We observed occasional β-gal + p-ERK1/2 + ISCs in Gpr182 lacZ/lacZ mice during homeostasis ( Figure 7B ). Significantly increased p-ERK1/2 was observed in Gpr182 lacZ/lacZ jejunum compared with Gpr182 +/+ controls, and this increase was observed during homeostasis, regeneration, and in Apc Min/+ polyps ( Figure 7C ). Interestingly, the increased organoid growth efficiency in Gpr182 Δ/Δ CD326 + CD44 + single cells was dependent on the addition of exogenous EGF (Supplemental Figure 7 , A-C). The expression of Egfr was not altered in Gpr182 Δ/Δ or Gpr182 lacZ/lacZ IRR jejunum compared with expression in controls (Supplemental Figure 7D) . These data suggest that EGF-mediated MAPK signaling is still required for the increased proliferative capacity of these Gpr182-null organoids.
Unlike ERK1/2 signaling, the phosphorylation of other signaling kinases, including p38 MAPK, AKT, STAT3, and YAP, appeared relatively unaltered in whole jejunum in Gpr182 +/+ and Gpr182 lacZ/lacZ mice (Supplemental Figure 8) . Therefore, the correlation between decreased Gpr182 and increased ERK1/2 signaling, along with the crypt and ISC localization of p-ERK1/2, especially during regeneration and in Apc Min/+ mice, suggests that GPR182 regulation of ERK1/2 occurs upstream of the increased proliferative capacity we observed in the Gpr182 lacZ/lacZ mice ( Figure 7D ).
GPR182 expression is reduced in numerous human carcinomas, including colon adenocarcinomas. Considering that reduced
Gpr182 increased the intestinal proliferative capacity in mice, we sought to determine whether GPR182 expression levels are changed in human carcinomas. First, we found that GPR182 expression was low in numerous human colorectal carcinoma cell lines, including CaCo2, HT29, Colo205, and SW480 (Supplemental Figure 9 ). Second, RNA-sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) (44, 45) confirmed Figure 8 . Low GPR182 expression in human carcinomas. Relative GPR182 expression determined by TCGA RNA-seq of patient-matched normal (N) and tumor (T) tissue. Bladder urothelial carcinoma (BLCA), n = 19; breast invasive carcinoma (BRCA), n = 98; cholangiocarcinoma (CHOL), n = 9; colon adenocarcinoma (COAD), n = 26; kidney chromophobe (KICH), n = 25; kidney renal clear cell carcinoma (KIRC), n = 71; kidney renal papillary cell carcinoma (KIRP), n = 32; liver hepatocellular carcinoma (LIHC), n = 50; lung adenocarcinoma (LUAD), n = 57; lung squamous cell carcinoma (LUSC), n = 50; pancreatic adenocarcinoma (PAAD), n = 58; rectum adenocarcinoma (READ), n = 6; stomach adenocarcinoma (STAD), n = 32; thyroid carcinoma (THCA), n = 57; uterine corpus endometrial carcinoma (UCEC), n = 7. *P < 0.05, **P < 0.01, and ***P < 0.001, by Wilcoxon matched-pairs, 2-tailed t test. jci.org Volume 127 Number 2 February 2017 and adenoma formation. Future studies to identify the ligand for this exciting and physiologically relevant orphan GPCR will shed light on its tractability as a potential therapeutic target.
Methods
Experimental animals. The Gpr182 tm2a(KOMP)Wtsi/+ (knockout first/promoter driven) mice used in this study were created from an embryonic stem (ES) cell clone (EPD0365_4_C08) obtained from the National Center for Research Resources-NIH-supported Knockout Mouse Project (KOMP) repository and generated by the CHORI, Sanger Institute, and UC Davis (CSD) Consortium for the NIH-funded KOMP (29) . The CSD-targeted allele has been previously published (62, 63) . To achieve ubiquitous deletion, Gpr182 tm2a(KOMP)Wtsi/+ mice were crossed with the B6.C-Tg(CMV-cre)1Cgn/J Tg mouse line (The Jackson Laboratory; stock no. 006054). For adenoma studies, Gpr182 lacZ/+ mice were crossed with the C57BL/6J-Apc
Min/+ /J mouse line (The Jackson Laboratory; stock no. 002020). All Gpr182-associated mouse lines were maintained on an isogenic C57BL/6 background. Previously published Sox9-EGFP BAC-Tg mice on a CD-1 background and C57BL/6 Lgr5-EGFP mice (The Jackson Laboratory; stock no. 008875) were used for cell isolation and expression verification (18, 19, 25, (30) (31) (32) . The genotyping primers used are listed in Supplemental Table 1 .
Animal procedures and dissection. For irradiation challenge, 10-to 14-week-old female Gpr182 +/+ and Gpr182 lacZ/lacZ mice were subjected to abdominal ionizing radiation as previously described (18) . Briefly, under isoflurane anesthesia, mice received 14 Gy radiation (50 cm, F1 Filter; X-Rad 320; Precision X-Ray) to their abdomens. Experimental and control mice were irradiated at the same time to ensure equivalent radiation dosages and rates (~2.8 Gy/min for 300 s). Mice were observed and weighed daily to monitor the severity of irradiation and overall health. Five days after irradiation, mice were injected i.p. with 4 μg 5-ethynyl-2′-deoxyuridine (EdU) per 1 g BW. After 90 minutes, mice were euthanized, and gastrointestinal tissue was collected for histology and biochemistry. For adenoma studies, male and female mice were monitored for health (physical appearance, BW, bloody stool) and euthanized for tissue collection at 5 months of age. The small intestines and colons were removed and flushed with cold PBS. The entire intestinal length was measured and then separated into duodenum, jejunum and ileum. The small intestines and colons from all Apc Min/+ mice were opened along the entire length, flattened, and macroscopic polyp numbers and sizes were quantified. Tissues were then processed for histology, whole-mount X-gal staining, and biochemistry. For cryogenic sections, tissue was fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and embedded in OCT before cryosectioning. For histology, tissues were fixed in either 4% paraformaldehyde or 10% zinc formalin and then paraffin embedded and sectioned. Single-cell isolation and ex vivo culture. Single cells from jejunum of 8-week-old female Gpr182 +/+ CMV-Cre and Gpr182 Δ/Δ CMV-Cre mice were isolated and cultured as previously described (31, 32, (40) (41) (42) 64) . Briefly, jejuna were flushed and incubated in 3 mM EDTA (Corning) and 10 μM Y27632 (Selleck Chemicals) in Dulbecco's PBS. Villi were gently scraped with a pipette tip, and the epithelium was separated from the submucosa by shaking. The epithelial crypts were further dissociated into single cells in 0.3 U/ml dispase (Thermo Fisher Scientific), 10 μg/ml DNase (Thermo Fisher Scientific), and Y27632 in HBSS. Single cells were stained with APC/Cy7-conjugated antifor maintaining intestinal health. However, under conditions of stress-induced proliferation, such as regeneration following injury, Apc Min mutation, or ex vivo culture in elevated Wnt signaling growth conditions, the reduction of Gpr182 caused hyperproliferative phenotypes, which were associated with elevated ERK1/2 signaling. Thus, we conclude that GPR182 normally functions to directly or indirectly inhibit MAPK-induced intestinal proliferation ( Figure 7D ). This inhibitory function is consistent with the finding that GPR182 expression is significantly reduced in human colon adenocarcinoma -a novel finding that expands the growing cadre of negative regulators of proliferation, including LRIG1, that have been shown to be downregulated during colorectal tumorigenesis (20, (46) (47) (48) (49) . Conversely, numerous pro-proliferative ISC markers, such as LGR5, BMI1, and SOX9, have all been shown to be upregulated in human colorectal carcinomas (50) .
MAPK signaling plays a critical role during regeneration and tumorigenesis, which is evidenced by the increased p-ERK1/2 localization within the crypt and ISCs during these conditions. Intestinal epithelial conditional deletion of ERK1/2 leads to rapid malabsorption and lethality (43) . ERK1/2 activation through surface receptors, such as TLR and/or EGFR, is required for adenoma formation in Apc Min/+ mice, which can be blocked by MEK/ERK inhibitors (51, 52) . In addition, loss of the RTK negative regulator Lrig1 leads to constitutively active EGFR and other ERbB receptors, which lead to increased ERK1/2 signaling, hyperproliferation, and tumorigenesis (20, 53) . Oncogenic mutations in KRAS activate numerous downstream kinases, including ERK1/2, which rarely initiate tumorigenesis alone but, when combined with Apc inactivation, lead to increased adenoma formation and progression (48, (54) (55) (56) (57) (58) . GPCRs can activate ERK1/2 directly through both G protein-and β-arrestin-mediated signaling, as well as indirectly through modulation of EGF/EGFR expression and/ or EGFR transactivation (59, 60 ). An activating mutation in Gsα (GNAS R201C) leads to increased cAMP and ERK1/2 activation, which increases adenoma formation when crossed with Apc + cells and in Gpr182 lacZ/lacZ IRR mice supports the notion that ErbB signaling may be enhanced in these mice and contributes to the hyperproliferative phenotypes. Additionally, organoids arising from single ISCs were dependent on the addition of exogenous EGF for the enhanced growth and survival observed in Gpr182 Δ/Δ ISCs. Thus, it remains possible that GPR182 could directly inhibit ERK1/2 through the reduction of cAMP levels and/or indirectly through the negative regulation of the EGFR signaling pathway. Alternatively, considering that the closest paralog to GPR182 is ACKR3, a member of the "decoy" atypical chemokine receptor subfamily, it is possible that the effects of GPR182 are manifested by its function as a nonsignaling ligand sink or "decoy" receptor. Unfortunately, until a ligand (or ligands) is identified, it is challenging and premature to try to delineate the precise signal transduction pathways that are directly associated with GPR182 activity in different cell types.
To our knowledge, this is the first study to use a genetic mouse model to simultaneously map Gpr182 localization patterns and elucidate novel physiological functions for the negative regulation of intestinal proliferative capacity, especially during regeneration jci. Real-time PCR analysis. Tissues were either snap-frozen in liquid nitrogen or stored in RNAlater (Ambion, Thermo Fisher Scientific). Enriched cell populations labeled with CD326 and CD44 or differential Sox9-EGFP or Lgr5-EGFP levels as previously described (18, 30, (40) (41) (42) were isolated by FACS and collected into RNAqueous-Micro Lysis Solution (Ambion, Thermo Fisher Scientific). Likewise, the Paneth cell-enriched population was isolated using a previously published protocol (31) . Human colorectal carcinoma cell lines (ATCC), HUVECs (Lonza), and human intestinal epithelial cells, provided by J.F. Beaulieu (University of Sherbrooke, Quebec, Canada), were cultured and collected as previously reported (66) . RNA was extracted using either TRIzol Reagent (Invitrogen, Thermo Fisher Scientific) and a Percellys bead homogenizer or RNAqueous-Micro Kit (Ambion, Thermo Fisher Scientific) according to standard procedures and then subsequently treated with DNase1 (RQ1; Promega) and reverse transcribed with M-MLV (Invitrogen, Thermo Fisher Scientific) or iScript (Bio-Rad Laboratories Whole-mount X-gal staining. Whole-mount X-gal staining was adapted from previously published protocols (19) . Briefly, whole tissue was fixed in 0.2% glutaraldehyde (Electron Microscopy Sciences) for 24 hours at 4°C. Tissue was washed and permeabilized with 0.1% triton and incubated in 1 mg/ml X-gal staining buffer (Bioline) for approximately 24 hours at room temperature in the dark. Tissue was washed and post-fixed in 4% paraformaldehyde for 24 hours at 4°C. Samples were washed, imaged, and paraffin embedded, and sections were counterstained with 1% Neutral Red solution (Sigma-Aldrich) or eosin.
Optical projection tomography. Whole-mount X-gal-stained tissues were embedded in 1% agarose (catalog 105128; Thermo Fisher Scientific), dehydrated overnight in absolute methanol, and cleared in benzyl alcohol/benzyl benzoate (1:2) as previously described (65) . Optically cleared specimens were mounted onto aluminum chucks and scanned with a 3001m Optical Projection Tomography Scanner (BiOPTonics) under bright-field illumination.
IHC. Paraffin and cryogenic sections were rehydrated, permeabilized, and blocked with 5% normal donkey serum. When required, slides were boiled in citrate buffer for antigen retrieval. Slides were then stained overnight at room temperature with the following primary antibodies: chicken anti-β-gal (1:1,500; catalog BGL-1040; Aves Labs Inc.); rabbit anti-lysozyme (1:1,000; catalog PA0391; Leica Biosystems); rabbit anti-p-histone H3 (1:500; catalog 9701; Cell Signaling Technology); rat anti-Ki67 (1:30; M7249; DakoCytomation); rabbit anti-p-ERK1/2 (1:300; catalog 4370; Cell Signaling Technology); rabbit anti-β-catenin (1:500; catalog ab16051; Abcam); rabbit anti-DCLK1 (1:1,000; catalog ab31704; Abcam); rat anti-CD31 (1:100; catalog ab56299; Abcam); and Syrian hamster anti-podoplanin (1: 
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Western blotting and analysis. Protein was extracted using Lens Homogenization Buffer with DTT and cOmplete Protease Inhibitor Cocktail Tablets (Roche) and a bead homogenizer (Percellys) according to standard procedures. Concentrations were determined using a Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific) read on a Mithras LB 940 Multimode Microplate Reader (Berthold Technologies). Protein was run on Mini-Protean TGX SDS-PAGE Gel (Bio-Rad Laboratories) and transferred onto a nitrocellulose (GE Healthcare) membrane. Blots were blocked and stained in 5% BSA diluted in TBS with 0.1% Tween-20. Blots were incubated overnight at 4°C with the following primary antibodies: rabbit anti-p42/44 MAPK (ERK1/2) (1:1,000; catalog 9102; Cell Signaling Technology); rabbit anti-p-p42/44 MAPK (ERK1/2) (Thr202/ Tyr204) (1:1,000; catalog 9101; Cell Signaling Technology); rabbit anti-AKT (1:1,000; catalog 4691; Cell Signaling Technology); rabbit anti-p-AKT (Ser473) (1:2,000; catalog 4060; Cell Signaling Technology); mouse anti-β-catenin (1:200; catalog 610153; BD Biosciences); rabbit anti-p38 MAPK (1:1,000; catalog 8690; Cell Signaling Technology); rabbit anti-p-p38 MAPK (Thr180/Tyr182) (1:1,000; catalog 9211; Cell Signaling Technology); mouse anti-STAT3 (1:1,000; catalog 9139; Cell Signaling Technology); rabbit anti-p-STAT3 (Tyr705) (1:2,000; catalog 9145; Cell Signaling Technology); rabbit anti-YAP (1:1,000; catalog 14074; Cell Signaling Technology); rabbit antip-YAP (Ser127) (1:1,000; catalog 13008; Cell Signaling Technology); and mouse anti-GAPDH (1:5,000; catalog NB300-285; Novus Biologicals). Blots were rinsed, blocked in 5% nonfat milk, and incubated in the dark for 60 minutes at room temperature with the following secondary antibodies: goat anti-rabbit DyLight 680 (1:12,000; catalog 35568; Thermo Fisher Scientific) and goat anti-mouse DyLight 800 (1:12,000; catalog SA5-10176; Thermo Fisher Scientific). An Odyssey CLx (LI-COR Biosciences) was used for imaging. Image brightness and contrast changes were made equally across all comparable images using Image Studio and Adobe Photoshop CS4. Phosphorylated and total protein quantification was analyzed by densitometry using ImageJ and normalized to Gpr182 +/+ controls. GAPDH was used to ensure equal loading. RNA-seq analysis. RNA-seq data were downloaded from the TCGA Data Portal (44, 45) . RSEM upper-quantile-normalized values from Illumina HiSeq _RNASeqV2 from patient-matched tumor and normal tissue were log 2 transformed. Samples with an expression value of 3 or lower were indistinguishable from background values and were thus considered a 0 value.
Statistics. Statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software), and all data are represented as the mean ± SEM. The unpaired or Mann-Whitney t test was used for data analysis of 2 groups with biological replicate numbers of less than 10 or more than 10, respectively. For parametric data with more than 2 comparisons and biological replicate numbers of less than 10, a 1-way ANOVA with Tukey's multiple comparisons test were used. For nonparametric
